Patent ID: 11873327
Assignee: MODERNATX, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 25:
26. A method of treating cancer in a subject in need thereof, comprising administering a LNP comprising a mRNA comprising a 5′ untranslated region (UTR), an ORF, and a 3′ UTR, wherein the ORF comprises a nucleotide sequence encoding from 5′ to 3′:
5′-[IL-12B]-[L1]-[IL-12A]-[L2]-[MD]-3′, wherein
IL-12B is a human IL-12 p40 subunit polypeptide comprising amino acids 23 to 328 of SEQ ID NO: 48,
L1 is a first peptide linker,
IL-12A is a human IL-12 p35 subunit polypeptide comprising amino acids 336 to 532 of SEQ ID NO: 48,
L2 is a second peptide linker, and
MD is a membrane domain comprising a CD80 transmembrane domain and a CD80 intracellular domain.